INT64386

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1996
Last Reported 2010
Negated 2
Speculated 0
Reported most in Abstract
Documents 13
Total Number 13
Disease Relevance 5.09
Pain Relevance 3.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Cyp11a1)
Anatomy Link Frequency
urine 1
Cyp11a1 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antidepressant 59 99.74 Very High Very High Very High
Versed 1 99.56 Very High Very High Very High
carbamazepine 5 99.08 Very High Very High Very High
Opioid 13 98.78 Very High Very High Very High
depression 107 97.92 Very High Very High Very High
antiepileptic Drug 8 94.20 High High
Lamotrigine 1 94.00 High High
Gabapentin 2 93.36 High High
Pain 5 91.12 High High
sNRI 25 90.00 High High
Disease Link Frequency Relevance Heat
Generalized Epilepsy 1 99.70 Very High Very High Very High
Epilepsy 12 98.52 Very High Very High Very High
Depression 142 97.92 Very High Very High Very High
Pulmonary Disease 1 97.44 Very High Very High Very High
Diabetes Mellitus 94 96.56 Very High Very High Very High
Adverse Drug Reaction 1 92.52 High High
Pain 5 91.12 High High
Ulcers 18 90.44 High High
Syndrome 5 88.40 High High
Disease 5 85.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pantoprazole, as a further development in PPIs, is characterized by improved pharmacokinetic behavior as well as by higher tissue selectivity and binding specificity and by a very low potential to interact with the cytochrome P450 enzyme system.
cytochrome P450 enzyme Binding (interact) of
1) Confidence 0.46 Published 1996 Journal The Yale Journal of Biology and Medicine Section Abstract Doc Link PMC2588986 Disease Relevance 0.51 Pain Relevance 0.14
BACKGROUND: Pantoprazole is a proton pump inhibitor characterized by a low potential to interact with the cytochrome P450 enzyme system in man.
cytochrome P450 enzyme Binding (interact) of
2) Confidence 0.40 Published 1996 Journal Aliment. Pharmacol. Ther. Section Abstract Doc Link 8791964 Disease Relevance 0 Pain Relevance 0.08
PHARMACOKINETIC INTERACTIONS: In vitro studies describe the reduced clearance of opioids in the presence of propofol, midazolam and etomidate due to interaction at the cytochrome P450 enzyme system.
cytochrome P450 enzyme Binding (interaction) of associated with versed and opioid
3) Confidence 0.40 Published 2001 Journal Acta Anaesthesiol Belg Section Abstract Doc Link 11799580 Disease Relevance 0 Pain Relevance 0.48
Pharmacol., 43, 207-208] is primarily due to an interaction of the inhibitory ipriflavone and/or its metabolites with cytochrome P450 enzyme(s) that mediate N-demethylation of theophylline.
cytochrome P450 enzyme Binding (interaction) of
4) Confidence 0.31 Published 1996 Journal Eur J Drug Metab Pharmacokinet Section Abstract Doc Link 8839679 Disease Relevance 0.10 Pain Relevance 0.04
Studies with purified enzymes show that StAR protein likely transports 7DHC to the inner mitochondrial membrane, that 7DHC can compete effectively with cholesterol for the substrate binding site on P450scc and that the catalytic efficiency of 3?
P450scc Binding (compete) of
5) Confidence 0.22 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2629546 Disease Relevance 0.07 Pain Relevance 0
Studies with purified enzymes show that StAR protein likely transports 7DHC to the inner mitochondrial membrane, that 7DHC can compete effectively with cholesterol for the substrate binding site on P450scc and that the catalytic efficiency of 3?
P450scc Binding (binding) of
6) Confidence 0.22 Published 2009 Journal PLoS ONE Section Abstract Doc Link PMC2629546 Disease Relevance 0.07 Pain Relevance 0
It is one of the rare antidepressants that has no interaction with the cytochrome P450 enzyme system,24 and thus possesses a very low risk of drug-drug interactions.
cytochrome P450 enzyme Neg (no) Binding (interaction) of associated with antidepressant
7) Confidence 0.16 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.13 Pain Relevance 0.78
The use of an antidepressant such as milnacipran, which has no interaction with any cytochrome P450 enzyme,24 reduces the risk of interactions.
cytochrome P450 enzyme Neg (no) Binding (interaction) of associated with antidepressant
8) Confidence 0.16 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2819761 Disease Relevance 1.03 Pain Relevance 0.46
Phenytoin (PHT), the most commonly used AED in this population, is extensively metabolized by the cytochrome P450 enzyme system, is highly protein bound, and interacts with many concomitant medications.
cytochrome P450 enzyme Binding (metabolized) of
9) Confidence 0.05 Published 2007 Journal Int. Rev. Neurobiol. Section Abstract Doc Link 17433926 Disease Relevance 0.09 Pain Relevance 0.25
Unlike the majority of antidepressants, milnacipran is only metabolized to a very minor extent, with most of the administered drug being excreted in the urine either unchanged or as the inactive glucurono-conjugate.15 Whereas most antidepressants interact with cytochrome P450 enzymes as inhibitors, inducers, or substrates,16 milnacipran has been shown to be essentially devoid of interactions with any cytochrome P450 enzyme.17 In addition, milnacipran binds to only a very limited extent (13%) to serum albumin.15 Milnacipran, therefore, has a low risk of pharmacokinetic drug-drug interactions.
cytochrome P450 enzyme Binding (interactions) of in urine associated with antidepressant
10) Confidence 0.03 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938282 Disease Relevance 0.46 Pain Relevance 0.52
As aliskiren does not affect cytochrome P450 enzyme activities, is minimally metabolised, and is not extensively protein bound, the potential for drug interactions is predicted to be low.
cytochrome P450 enzyme Binding (bound) of
11) Confidence 0.02 Published 2006 Journal Int. J. Clin. Pract. Section Abstract Doc Link 17073832 Disease Relevance 0.07 Pain Relevance 0
Currently, five PPIs are marketed: rabeprazole, omeprazole, esomeprazole, lansoprazole and pantoprazole, each with a different pharmacokinetic profile, tissue selectivity, binding specificity and potential to interact with the cytochrome P450 enzyme system [8-10].
cytochrome P450 enzyme Binding (interact) of
12) Confidence 0.01 Published 2002 Journal BMC Gastroenterol Section Body Doc Link PMC117603 Disease Relevance 0.77 Pain Relevance 0.04
Women without epilepsy (23 controls) and women with localization-related epilepsy (LRE, n = 59) or idiopathic (primary) generalized epilepsy (IGE, n = 35) receiving either a cytochrome P450 enzyme (cP450) inducing AED (carbamazepine, phenytoin, and phenobarbital), a cP450 inhibiting AED (valproate), or an AED that does not alter cP450 enzymes (lamotrigine and gabapentin) in monotherapy for 6 months or more were followed for three menstrual cycles.
cytochrome P450 enzyme Binding (receiving) of associated with epilepsy, lamotrigine, generalized epilepsy, gabapentin and carbamazepine
13) Confidence 0.01 Published 2002 Journal Ann. Neurol. Section Abstract Doc Link 12447923 Disease Relevance 0.79 Pain Relevance 0.23

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox